Antilipidemic drugs. Part 2: Experimental study of a new potent hypolipidemic drug, isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-propionate (LF178).

Pharmacological investigations have been carried out on a new p-chlorobenzoyl substituted phenoxy-isobutyric acid derivate with potent antilipidemic activity, isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]propionate (LF 178; procetofene; Lipanthyl¿). The compound depressed total lipids and total cholesterol significantly in the normal rat from 15-20 mg/kg upwards. At 100 mg/kg, the drug-induced depression of total lipids was twice the effect observed with 300 mg/kg of clofibrate. Significant depression of lipid parameters was induced in the senescent rat, in the dietary hyperlipidemic and in the triton hyperlipidemic rat. In the two last models clofibrate failed to affect lipid parameters at 300 mg/kg. The absence of pharmacological side effects indicates a high pharmacological specificity with respect to lipid metabolism. It might be concluded that LF 178 presents an antilipidemic profile different from the well known hypolipidemic drug clofibrate.